Mohit Manrao: The latest challenges and scientific advances in blood cancer
Mohit Manrao shared on LinkedIn:
“This post is intended for a US audience only.
I’m at the American Society of Hematology (ASH) 2024 Annual Meeting with many of my AstraZeneca and Alexion colleagues to learn about the latest challenges and scientific advances in blood cancer, as well as share the contributions we are making in hematology.
Today, interim results from our AMPLIFY Phase III study for patients living with chronic lymphocytic leukemia (CLL) were showcased in the ASH Annual Meeting Press Program and will take center stage during an oral presentation tomorrow.
CLL is one of the most common types of leukemia in adults, with an estimated 20,700 new cases diagnosed in the United States this year. This disease remains incurable and chronic, requiring long-term management. Our work is driven by our goal of changing the practice of medicine and transforming the lives of patients living with blood cancer. I’m proud to share how we’re working toward this for CLL during tomorrow’s presentation. ”
More posts featuring Mohit Manrao.
Mohit Manrao is the SVP and Head of US Oncology at AstraZeneca and President of the AstraZeneca Foundation, where he leads community grant programs. As Executive Sponsor of AstraZeneca’s US Health Equity Initiative, he focuses on reducing healthcare disparities. He also serves as a Board Member of the National Pharmaceutical Council.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023